Factors associated with viral RNA shedding and evaluation of potential viral infectivity at returning to school in influenza outpatients after treatment with baloxavir marboxil and neuraminidase inhibitors during 2013/2014–2019/2020 seasons in Japan: an observational study

Table 2 Median viral clearance between influenza A and B infected patients

Characteristics	Influenza A	Influenza B	p^a
Characteristics	Median (IQR) (log₁₀/day)	Median (IQR) (log₁₀/day)	p^a
Age group
0–5 years	0.56 (0.38–0.85)	0.28 (0.18–0.69)	0.053
6–18 years	0.76 (0.51–1.06)	0.65 (0.38–0.92)	0.029
≥ 19 years	0.87 (0.61–1.01)	0.65 (0.55–0.86)	0.398
Treatment
Baloxavir	0.81 (0.52–1.12)	0.77 (0.38–1.04)	0.440
Laninamivir	0.76 (0.45–1.06)	0.37 (0.29–0.56)	0.014
Oseltamivir	0.63 (0.44–0.93)	0.64 (0.48–0.86)	0.636
Zanamivir	0.90 (0.65–1.08)	0.55 (0.27–0.77)	0.018
Vaccination status
Unvaccinated	0.72 (0.49–1.00)	0.63 (0.35–0.89)	0.029
Vaccinated	0.77 (0.49–1.06)	0.65 (0.47–0.87)	0.189
PA variants
No	0.73 (0.48–1.01)	NA	< 0.001
Yes	0.42 (0.28–0.56)	NA	< 0.001

ISSN: 1471-2334